ATXA Therapeutics

Professor Therese Kinsella, the founder and CEO of ATXA Therapeutics, a clinical-stage pharmaceutical company, and a spin-out of the UCD School of Molecular and Biomedical Science, has been named the recipient of the 2024 NovaUCD Innovation Award. ATXA is based on research which she and her team carried out at the UCD Conway Institute over 20 years which was funded by Enterprise Ireland, the Welcome Trust, Irish Cancer Society, Health Research Board (HRB), Science Foundation Ireland, and Irish Heart Foundation, amongst others. ATXA’s focus is the development of its lead candidate drug NTP42 for the treatment of Pulmonary Arterial Hypertension (PAH). PAH is a devastating disease of the lungs and heart with an urgent unmet need for new improved therapies. Through NTP42, which has orphan drug designations from both the EMA in Europe and the FDA in the US, ATXA aims to offer improved treatment options to prescribing physicians and the company has successfully completed initial First-in-Human Phase I clinical trials for NTP42 in healthy male volunteers. Professor Therese Kinsella, CEO and Founder, ATXA Therapeutics, said, “It is indeed a great honour for me to accept this Award from UCD both personally and on behalf of everyone on the ATXA team who have been part of our success journey so far.” She added, “The company is working towards commencing Phase II clinical trials in PAH patients to demonstrate NTP42’s clinical efficiency. Depending on securing approval from the EMA and FDA regulatory agencies, as well as the necessary inward investment, the Phase II trials are due to run from 2025 through to late 2026.” The company has raised over €17 million in funding (equity and grant) to date and funders include the European Innovation Council Accelerator Programme, Horizon 2020 SME Instrument Programme, Enterprise Ireland and private investors. In addition Professor Kinsella and ATXA have a patent estate of 16 granted patents, in Europe, USA, Canada, Japan, and Australia, with numerous others filed globally protecting their drugs out to the mid-2040s. Find out more: https://lnkd.in/epdjcUKu UCD Research

NovaUCD has today announced the recipients of its annual innovation awards, which highlight successes made in areas of knowledge transfer, consultancy, entrepreneurship and the promotion of an innovation culture, by members of the UCD research, innovation and entrepreneurial community. A total of 7 Awards, including the main 2024 NovaUCD Innovation Award, were presented by Professor Orla Feely, President, UCD during an event held in the UCD University Club. Speaking at the event Professor Orla Feely, said, “The NovaUCD Innovation Awards have become a key annual event highlighting the University’s commitment to innovation and recognise the achievements of our research, innovation and entrepreneurial communities and I congratulate all who have received this year’s Awards. I would also like to wish the Awardees future success as they continue to work towards delivering economic and societal impact in Ireland, and further afield, through their commercialisation, consultancy, entrepreneurial and innovation activities.” Congratulations to all of this year's Awardees. 2024 NovaUCD Innovation Award: Professor Therese Kinsella, CEO and founder, ATXA Therapeutics. 2024 NovaUCD Invention of the Year Award: Associate Professor Nan Zhang, UCD School of Mechanical and Materials Engineering. 2024 NovaUCD Spin-out of the Year Award: EpiCapture Limited 2024 NovaUCD Consultancy of the Year Award: Professor Fiona Timmins, UCD School of School of Nursing, Midwifery and Health Systems 2024 NovaUCD Licence of the Year Award: Go Eve 2024 NovaUCD Founder of the Year Award: John Byrne, CEO and Founder, Corlytics 2024 NovaUCD Innovation Champion of the Year Award: Professor Nicholas Holden, UCD School of Biosystems and Food Engineering. Read the full story via: https://lnkd.in/e9DXy4z5 University College Dublin UCD Research AgTechUCD Innovation Centre ConsultUCD UCD EngArch UCD College of Health and Agricultural Sciences Knowledge Transfer Ireland (KTI) Edward Simons Kevin Tansley Robert Shorten John Goodbody Andrew Cullen Pietro Ferraro.

Professor Therese Kinsella, Founder and CEO of ATXA Therapeutics, was the recipient of the main 2024 NovaUCD Innovation Award during an event held in the UCD University Club on April 11, 2024. These annual awards recognise excellence in innovation and of the successes achieved in the commercialisation of University College Dublin research over a number of years.

🚨 IT'S OFFICIALLY RARE DISEASE DAY ACROSS THE GLOBE 🚨 Join us in marking Rare Disease Day 2024 now that it's finally here! Let's unite in solidarity with the millions worldwide living with rare diseases. 🌍 Spread awareness, share stories, and show support for them. Together, we can make a lasting impact and shine a light on these often overlooked! Let's make today count by raising awareness and advocating for those who need it most. Every voice matters in the fight for understanding and support. Visit our website to find out more:https://lnkd.in/gk6hbAF . . #RareDiseaseDay #ShareYourColours #LightUpForRare #Awareness

Why is it important to raise awareness?🤔 Bringing awareness to rare diseases is crucial as it sheds light on the specific challenges faced by those affected. From struggling to get a correct diagnosis due to limited knowledge among healthcare professionals to the financial burden of accessing expensive treatments, people often face uphill battles. Moreover, the absence of tailored support networks can lead to feelings of isolation and misunderstanding. By sharing their stories and advocating for greater understanding, we can pave the way for improved resources, research, and ultimately, better quality of life. 💙 . . #RareDiseaseDay #ShareYourColours #LightUpForRare #Awareness

Countdown alert! Just 10 days left until Rare Disease Day! 🎉 Let's come together to raise awareness and support for those living with rare conditions. Got something special planned? Don't forget to submit your events! Illuminate the world in solidarity with #LightUpForRare 💡, advocate for better resources and understanding, and share our stories to inspire change. Together, we're stronger! 💪 . . #RareDiseaseDay #Awareness #LightUpForRare #ShareYourColours

Great to see so many current and graduate NovaUCD client companies featured in Spark CrowdFunding's 2024 Top 100 Most Ambitious Companies in Ireland. Agri Data Analytics Atturos Ltd ATXA Therapeutics Cotter Agritech Customs Window Lios Manna Drone Delivery nanobOx OptaHaul ReaDI-Watch SizeWise Sports Impact Technologies TrojanTrack Well Spent Grain ltd. Nice way to start 2024.... Congrats to all the 100 companies featured. AgTechUCD Innovation Centre

IRELAND'S TOP 100 MOST AMBITIOUS COMPANIES - JUST UNVEILED. Celebrating innovation, resilience, and the visionary spirit driving Ireland's business landscape. Discover the trailblazers shaping our future! 🚀 Please RE-POST. https://lnkd.in/e6eed2Ri

On behalf of all at ATXA, we wish you all a happy and peaceful holiday season and the very best for the New Year!

In first-in-human Phase 1 trials, ATXA Therapeutics' NTP42:KVA4 is safe and well tolerated, with favorable PK/PD characteristics and evidence of specific TP target engagement. These findings, combined with compelling preclinical efficacy data, support the continued development of #NTP42 for the treatment of cardiopulmonary diseases, including #PAH. Check out our paper, published today in Frontiers in Pharmacology... https://lnkd.in/ervCww9M